SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 2, 2012
(Exact name of registrant as specified in its charter)
(State or other jurisdiction
3530 Toringdon Way, Suite 200, Charlotte, North Carolina 28277
(Address of principal executive offices) (Zip Code)
Registrants telephone number, including area code (704) 341-1516
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|¨||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|¨||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|¨||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|¨||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
|Item 8.01.||Other Events.|
On May 2, 2012, a purported shareholder derivative lawsuit was filed in the Delaware Court of Chancery against the directors of Chelsea Therapeutics International, Ltd.: Verma v. Pedder et al.
The complaint generally alleges that, from at least June 2011 through February 2012, the defendants breached their fiduciary duties and otherwise caused harm to Chelsea in connection with various statements related to Chelseas development of Northera (droxidopa) for the treatment of symptomatic neurogenic orthostatic hypotension (NOH) and the likelihood of FDA approval. The complaint seeks unspecified damages, attorneys fees and other costs. Additional similar lawsuits might be filed.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|CHELSEA THERAPEUTICS INTERNATIONAL, LTD.|
|Date: May 4, 2012|
|J. Nick Riehle, Chief Financial Officer|